



# PRESS RELEASE

## Indoco Q3 revenues grew 7 % YoY

**Mumbai, February 3, 2026 :** During the third quarter of FY 2025-26, revenues of Indoco Remedies are at ₹ 3,896 mn, as against ₹ 3,649 mn, in the same quarter last year, registering a 7 % revenue growth. EBIDTA for the quarter is at ₹ 259 mn, compared to ₹ 201 mn in the same quarter last year, registering a 29 % growth.

*Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The revenue growth in this quarter is mainly due to the Export Formulations business and API business."*

### About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, OxiPod, Cital, Senoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

### For Media Inquiries Please Contact:



Mr. Anuj Sonpal  
Valorem Advisors  
Tel: +91-22-4903-9500  
Email:  
[indoco@valoremadvisors.com](mailto:indoco@valoremadvisors.com)/[corpcom@indoco.com](mailto:corpcom@indoco.com)